During 2012, the Chilean Antitrust case denominated “Pharmacies” became one of the leading in terms of investigation conducted by the Fiscalia Nacional Economica and one of the highlighted decisions of the Antitrust Court, Tribunal de Defensa de la Libre Competencia. This paper analyses the basic structure of judgement 119/2012 issued by the Tribunal, and confirmed by Chilean Supreme Court, by decision 2578-2012, which it was written by judge Sergio Muñoz, rejecting an appeal issued by Cruz Verde S.A and Salcobrand S.A. The article also studies the way by which the judges define the relevant market, and discusses some elements about parallel pricing. Furthermore, the case was controversial with respect to to the application of an agreement of conciliation with FASA S.A.
Full Content: SSRN
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI